This is an excerpt from the original initial Phase IIb AIPAC results way back in March 25, 2020.
"AIPAC Principal Investigator, Hans Wildiers of University Hospitals Leuven, Leuven, Belgium, said: “I am
pleased to see this innovative chemo-immunotherapy approach in AIPAC is well tolerated by patients, while
showing a numerically (non-significant) higher progression free survival rate compared to chemotherapy
alone."
Which I guess speaks to the statistical significance of these results...
Ann: New & significant data from AIPAC phase 2b trial in MBC, page-9
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $365.0M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 24.0¢ | $664.5K | 2.729M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 40000 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 13143 | 3 |
View Market Depth
| Last trade - 16.10pm 08/07/2025 (20 minute delay) ? |
| IMM (ASX) Chart |